Value-based drug pricing backed19th September 2008
Conservative shadow health secretary Andrew Lansley has said that pharmaceutical companies should be paid according to the benefits that their drugs bring to patients.
Speaking to the Confederation of British Industry, Mr Lansley called for a partnership between the NHS and the pharmaceutical industry in a bid to make the latest cancer drugs available to patients. He highlighted Johnson & Johnson's risk-sharing deal on Velcade for the treatment of multiple myeloma and Novartis's offer on Lucentis for the treatment of wet age-related macular degeneration.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Value-based drug pricing backed
Author: Mark Nicholls
Article Id: 8437
Date Added: 19th Sep 2008